Role of dihydropyridinic calcium channel blockers in the management of hypertension

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 1, 2013, Pages 91-105

  Coca, Antonio ^a   Mazón, Pilar ^b   Aranda, Pedro ^c   Redón, Josep ^d   Divisón, Juan Antonio ^e   Martínez, Javier ^b,f   Calvo, Carlos ^b   Galcerán, Josep María ^g   Barrios, Vivencio ^h   Coll, Alexandre Roca Cusachs I ⁱ  

^a UNIVERSITY OF BARCELONA   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e Casas Ibáñez Primary Care Center   (Spain)

^f HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^g Althaia   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

amlodipine; antihypertensive treatment; dihydropyridinic; hypertension; L type calcium channel blocker; manidipine; T type calcium channel blocker

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LACIDIPINE; LISINOPRIL; MANIDIPINE; NIFEDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ADRENERGIC ACTIVITY; ANGINA PECTORIS; ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL WALL THICKNESS; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC HYPERTENSION; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FLUSHING; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOTENSION; LIPOPHILICITY; LOW DRUG DOSE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; NEOPLASM; PLEIOTROPY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 84871558302     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.155     Document Type: Review

References (123)

1. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J . Worldwide prevalence of hypertension: A systematic review. J. Hypertens. 22 (1), 11 - 19 (2004
2. Staessen JA, Wang JG, Thijs L . Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J. Hypertens. 21 (6), 1055 - 1076 (2003
3. Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension . Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J. Hypertens. 27 (11), 2121 - 2158 (2009
4. Richard S . Vascular effects of calcium channel antagonists: New evidence. Drugs 65 (SUPPL2), 1 - 10 (2005
5. Beltrame JF, Turner SP, Leslie SL, Solomon P, Freedman SB, Horowitz JD . The angiographic and clinical benefi ts of mibefradil in the coronary slow fl ow phenomenon. J. Am. Coll. Cardiol. 44 (1), 57 - 62 (2004
6. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T . Ca 2+ channel subtypes and pharmacology in the kidney. Circ. Res. 100 (3), 342 - 353 (2007
7. Spedding M, Paoletti R . Classifi cation of calcium channels and the sites of action of drugs modifying channel function. Pharmacol. Rev. 44 (3), 363 - 376 (1992
8. Hajjar I, Kotchen TA . Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2), 199 - 206 (2003
9. Thomas F, Rudnichi A, Bacri AM, Bean K, Guize L, Benetos A . Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 37 (5), 1256 - 1261 (2001
10. Mancia G, De Backer G, Dominiczak A et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology . 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25 (6), 1105 - 1187 (2007
11. Law MR, Morris JK, Wald NJ . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009
12. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 (9080), 757 - 764 (1997
13. Liu L, Wang JG, Gong L, Liu G, Staessen JA . Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J. Hypertens. 16 (12 PT1), 1823 - 1829 (1998
14. Morgan TO, Anderson AI, MacInnis RJ . ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens. 14 (3), 241 - 247 (2001
15. Neutel JM, Smith DH, Wallin D et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am. J. Hypertens. 7 (7 PT1), 623 - 628 (1994
16. Neaton JD, Primeas RJ, Flack JM et al. Long-term antihypertensive effect of different classes of antihypertensive drugs in mild hypertension: Treatment of Mild Hypertension Study (TOMHS). JAMA 270 (6), 713 - 724 (1993
17. Fogari R, Zoppi A, Corradi L, Preti P, Malalamani GD, Mugellini A . Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J. Hypertens. 18 (12), 1871 - 1875 (2000
18. Payeras AC, Sladek K, Lembo G, Alberici M . Antihypertensive Effi cacy and Safety of Manidipine Versus Amlodipine in Elderly Subjects with Isolated Systolic Hypertension: MAISH study. Clin. Drug Investig. 27 (9), 623 - 632 (2007
19. Richy FF, Laurent S . Effi cacy and safety profi les of manidipine compared with amlodipine: A meta-analysis of head-to-head trials. Blood Press. 20 (1), 54 - 59 (2011
20. Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofl umethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366 (9489), 895 - 906 (2005
21. Julius S, Kjeldsen SE, Weber M et al.; VALUE Trial Group . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363 (9426), 2022 - 2031 (2004
22. Ogihara T, Nakao K, Fukui T et al.; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group . Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 51 (2), 393 - 398 (2008
23. Roca-Cusachs A, Triposkiadis F . Antihypertensive effect of manidipine. Drugs 65 (SUPPL2), 11 - 19 (2005
24. Law MR, Wald NJ, Morris JK, Jordan RE . Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 326 (7404), 1427 (2003
25. Williams B, Lacy PS, Thom SM et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee . Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (9), 1213 - 1225 (2006
26. Saunders E, Weir MR, Kong BW et al. A comparison of the effi cacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch. Intern. Med. 150 (8), 1707 - 1713 (1990
27. Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. 328 (13), 914 - 921 (1993
28. Neutel JM . The use of combination drug therapy in the treatment of hypertension. Prog. Cardiovasc. Nurs. 17 (2), 81 - 88 (2002
29. ALLHAT Offi cers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (23), 2981 - 2997 (2002
30. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (9118), 1755 - 1762 (1998
31. Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (9311), 995 - 1003 (2002
32. Lewis EJ, Hunsicker LG, Clarke WR et al.; Collaborative Study Group . Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345 (12), 851 - 860 (2001
33. Cushman WC, Ford CE, Cutler JA et al.; ALLHAT Collaborative Research Group . Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 4 (6), 393 - 404 (2002
34. Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359 (23), 2417 - 2428 (2008
35. Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the effi cacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther. 29 (4), 563 - 580 (2007
36. Poldermans D, Glazes R, Kargiannis S et al. Tolerability and blood pressurelowering effi cacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 29 (2), 279 - 289 (2007
37. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ . Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122 (3), 290 - 300 (2009
38. Malacco E, Varì N, Capuano V, Spagnuolo V, Borgnino C, Palatini P; Val-Syst study . A randomized, doubleblind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clin. Ther. 25 (11), 2765 - 2780 (2003
39. Epstein M . Calcium antagonists in the management of hypertension. In: Calcium Antagonists in Clinical Medicine. Epstein M (Ed.). Hanley and Belfus Inc., PA, USA, 293 - 313 (2002
40. Weir MR, Rosenberger C, Fink JC . Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am. J. Hypertens. 14 (9 PT1), 963 - 968 (2001
41. Messerli FH . Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists. Am. J. Hypertens. 12 (8 PT2), S86 - S90 (1999
42. Messerli FH, Weir MR, Neutel JM . Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am. J. Hypertens. 15 (6), 550 - 556 (2002
43. Fogari R, Malamani GD, Savino S et al. Effects of different dihydropyridine calcium antagonists on pretibial subcutaneous tissue pressure in hypertensive patients. Am. J. Hypertens. 11 (SUPPL3) (1998) (Abstract 114A
44. Tikhonoff V, Mazza A, Casiglia E . Differential effects of manidipine and lercanidipine on blood pressure, peripheral circulation and ankle oedema in hypertensive patients. J. Hypertens. 22 (SUPPL2) (2004) (Abstract 244A
45. Pavlicevi I, Kuzmani M, Rumboldt M, Rumboldt Z . Interaction between antihypertensives and non-steroidal anti-infl ammatory drugs in primary care: A controlled trial. Can. J. Clin. Pharmacol. 15 (3), e372 - e382 (2008
46. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274 (8), 620 - 625 (1995
47. Furberg CD, Psaty BM, Meyer JV . Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92 (5), 1326 - 1331 (1995
48. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ . Do calcium channel blockers increase the risk of cancer? Am. J. Hypertens. 9 (7), 695 - 699 (1996
49. Braun S, Boyko V, Behar S et al. Calcium antagonists and mortality in patients with coronary artery disease: A cohort study of 11,575 patients. J. Am. Coll. Cardiol. 28 (1), 7 - 11 (1996
50. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356 (9246), 1955 - 1964 (2000
51. Epstein BJ, Vogel K, Palmer BF . Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67 (9), 1309 - 1327 (2007
52. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration . Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362 (9395), 1527 - 1535 (2003
53. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N. Engl. J. Med. 335 (15), 1107 - 1114 (1996
54. Costanzo P, Perrone-Filardi P, Petretta M et al. Calcium channel blockers and cardiovascular outcomes: A meta-analysis of 175,634 patients. J. Hypertens. 27 (6), 1136 - 1151 (2009
55. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP . Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322 (22), 1561 - 1566 (1990
56. Barrios V, Escobar C, Calderon A, Ribas L, Marti D, Asin E . Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press. 17 (2), 110 - 115 (2008
57. Barrios V, Calderón A, Escobar C et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: The SARA study. J. Hypertens. 25 (9), 1967 - 1973 (2007
58. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A meta-analysis. Am. J. Hypertens. 16 (11 PT1), 895 - 899 (2003
59. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115 (1), 41 - 46 (2003
60. Fagard RH, Celis H, Thijs L, Wouters S . Regression of left ventricular mass by antihypertensive treatment: A meta-analysis of randomized comparative studies. Hypertension 54 (5), 1084 - 1091 (2009
61. Grobbee DE, Bots ML . Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 236 (5), 567 - 573 (1994
62. Simon A, Gariépy J, Moyse D, Levenson J . Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 103 (24), 2949 - 2954 (2001
63. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102 (13), 1503 - 1510 (2000
64. Zanchetti A, Bond MG, Hennig M et al.; ELSA Investigators . Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: Further results of the European Lacidipine Study on Atherosclerosis (ELSA). J. Hypertens. 22 (6), 1201 - 1212 (2004
65. ENCORE Investigators. Effects of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease. The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin on Recovery of Coronary Endothelial Function). Circulation 107 (3), 422 - 428 (2003
66. Mason RP, Marche P, Hintze TH . Novel vascular biology of third-generation L -type calcium channel antagonists: Ancillary actions of amlodipine. Arterioscler. Thromb. Vasc. Biol. 23 (12), 2155 - 2163 (2003
67. Ishii N, Matsumura T, Shimoda S, Araki E . Anti-atherosclerotic potential of dihydropyridine calcium channel blockers. J. Atheroscler. Thromb. 19 (8), 693 - 704 (2012
68. Preston Mason R . Pleiotropic effects of calcium channel blockers. Curr. Hypertens. Rep. 14 (4), 293 - 303 (2012
69. Buset Ríos N, Rodríguez Esparragón F, Fernández-Andrade Rodríguez C, Rodríguez Pérez JC . [Vascular and metabolic properties of manidipine.] Nefrologia 31 (3), 268 - 274 (2011
70. Hillege HL, Fidler V, Diercks GF et al.; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group . Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (14), 1777 - 1782 (2002
71. Wright JT Jr, Bakris G, Greene T et al.; African American Study of Kidney Disease and Hypertension Study Group . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288 (19), 2421 - 2431 (2002
72. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF . Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefi ts of calcium channel blockers? K idney Int. 53 (6), 1559 - 1573 (1998
73. Jafar TH, Stark PC, Schmid CH et al.; AIPRD Study Group . Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann. Intern. Med. 139 (4), 244 - 252 (2003
74. Bakris GL . Maximizing cardiorenal benefi t in the management of hypertension: Achieve blood pressure goals. J. Clin. Hypertens. (Greenwich) 1 (2), 141 - 147 (1999
75. Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J. Am. Soc. Nephrol. 16 (10), 3027 - 3037 (2005
76. Bakris GL, Sarafi dis PA, Weir MR et al.; ACCOMPLISH Trial Investigators . Renal Outcomes with Different Fixed-Dose Combination Therapies in Patients with Hypertension at High Risk for Cardiovascular Events (ACCOMPLISH): A prespecifi ed secondary analysis of a randomised controlled trial. Lancet 375 (9721), 1173 - 1181 (2010
77. Jafar TH, Stark PC, Schmid CH et al.; AIPRD Study Group. Angiotensinconverting enzyme inhibition and progression of renal disease . Proteinuria as a modifi able risk factor for the progression of non-diabetic renal disease. Kidney Int. 60 (3), 1131 - 1140 (2001
78. Fogari R, Preti P, Zoppi A et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive Type 2 diabetic patients. Am. J. Hypertens. 15 (12), 1042 - 1049 (2002
79. Nakagawa N, Fujino T, Kabara M et al.; NICE-Combi Study Group . Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular fi ltration rate. Hypertens. Res. 34 (10), 1121 - 1126 (2011
80. Furukawa T, Nukada T, Miura R et al. Differential blocking action of dihydropyridine Ca 2+ antagonists on a T-type Ca 2+ channel (α-1G) expressed in Xenopus oocytes. J. Cardiovasc. Pharmacol. 45 (3), 241 - 246 (2005
81. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T . Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am. J. Nephrol. 23 (4), 229 - 244 (2003
82. Martinez-Martin FJ, Saiz-Satjes M . Add-on Manidipine Versus Amlodipine in Diabetic Patients with Hypertension and Microalbuminuria: The AMANDHA study. Expert Rev. Cardiovasc. Ther. 6 (10), 1347 - 1355 (2008
83. Alberti KG, Eckel RH, Grundy SM et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity . Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (16), 1640 - 1645 (2009
84. Cameron A . The metabolic syndrome: Validity and utility of clinical defi nitions for cardiovascular disease and diabetes risk prediction. Maturitas 65 (2), 117 - 121 (2010
85. Ferrannini E, Haffner SM, Mitchell BD, Stern MP . Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome. Diabetologia 34 (6), 416 - 422 (1991
86. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. 321 (13), 868 - 873 (1989
87. Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S . Metabolic effects of diltiazem and atenolol: Results from a randomized, double-blind study with parallel groups. J. Hypertens. 7 (7), 551 - 559 (1989
88. Elliott WJ, Meyer PM . Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 369 (9557), 201 - 207 (2007
89. Tuomilehto J, Rastenyte D, Birkenhäger WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 340 (9), 677 - 684 (1999
90. Weber MA, Bakris GL, Jamerson K et al.; ACCOMPLISH Investigators . Cardiovascular events during differing hypertension therapies in patients with diabetes. J. Am. Coll. Cardiol. 56 (1), 77 - 85 (2010
91. Ruggenenti P, Lauria G, Iliev IP et al.; DEMAND Study Investigators . Effects of manidipine and delapril in hypertensive patients with Type 2 diabetes mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial. Hypertension 58 (5), 776 - 783 (2011
92. Martínez Martín FJ . Manidipine in hypertensive patients with metabolic syndrome: The MARIMBA study. Expert Rev. Cardiovasc. Ther. 7 (7), 863 - 869 (2009
93. Suzuki M, Kanazawa A, Hasegawa M, Harano Y . Improvement of insulin resistance in essential hypertension by long-acting Ca antagonist benidipine. Clin. Exp. Hypertens. 21 (8), 1327 - 1344 (1999
94. Martinez-Martin FJ, Macias-Batista A, Comi-Diaz C, Rodriguez-Rosas H, Soriano-Perera P, Pedrianes-Martin P . Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, infl ammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: The MARCADOR study. Clin. Drug Investig. 31 (3), 201 - 212 (2011
95. Nakami T . PPAR-gamma activation by manidipine mediates enhanced adiponectin production and insulin sensitivity. J. Hypertens. 24 (SUPPL6), S161 (2006
96. Martell-Claros N, de la Cruz JJ . Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: A non-comparative, open-label study. Clin. Drug Investig. 31 (6), 427 - 434 (2011
97. Koh KK, Quon MJ, Lee SJ et al. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. Diabetes Care 30 (6), 1605 - 1607 (2007
98. Blacher J, Staessen JA, Girerd X et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch. Intern. Med. 160 (8), 1085 - 1089 (2000
99. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials. Lancet 355 (9207), 865 - 872 (2000
100. Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee . The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289 (19), 2560 - 2572 (2003
101. Turnbull F, Neal B, Ninomiya T et al.; Blood Pressure Lowering Treatment Trialists' Collaboration . Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. BMJ 336 (7653), 1121 - 1123 (2008
102. Di Bari M, Pahor M, Franse LV et al. Dementia and disability outcomes in large hypertension trials: Lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am. J. Epidemiol. 153 (1), 72 - 78 (2001
103. Wang JG, Staessen JA, Li Y et al. Carotid intima-media thickness and antihypertensive treatment: A meta-analysis of randomized controlled trials. Stroke 37 (7), 1933 - 1940 (2006
104. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration . Age-specifi c relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (9349), 1903 - 1913 (2002
105. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363 (9426), 2049 - 2051 (2004
106. Leenen FH, Nwachuku CE, Black HR et al.; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group . Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48 (3), 374 - 384 (2006
107. Nissen SE, Tuzcu EM, Libby P et al.; CAMELOT Investigators . Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 292 (18), 2217 - 2225 (2004
108. Poole-Wilson PA, Lubsen J, Kirwan BA et al.; Coronary Disease Trial Investigating Outcome with Nifedipine Gastrointestinal Therapeutic System Investigators . Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial. Lancet 364 (9437), 849 - 857 (2004
109. Dargie HJ, Ford I, Fox KM; Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur. Heart J. 17 (1), 104 - 112 (1996
110. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.; INVEST Investigators . A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290 (21), 2805 - 2816 (2003
111. Lloyd-Jones D, Adams R, Carnethon M et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (3), 480 - 486 (2009
112. Khan NA, Hemmelgarn B, Herman RJ et al.; Canadian Hypertension Education Program . The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can. J. Cardiol. 25 (5), 287 - 298 (2009
113. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group . The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebocontrolled trial in Chinese hypertensive patients. J. Hypertens. 23 (12), 2157 - 2172 (2005
114. Schrader J, Lüders S, Kulschewski A et al.; MOSES Study Group . Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke. 36 (6), 1218 - 1226 (2005
115. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 358 (9287), 1033 - 1041 (2001
116. Lithell H, Hansson L, Skoog I et al.; SCOPE Study Group . The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J. Hypertens. 21 (5), 875 - 886 (2003
117. Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46 (2), 386 - 392 (2005
118. Webb AJ, Fischer U, Mehta Z, Rothwell PM . Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: A systematic review and meta-analysis. Lancet 375 (9718), 906 - 915 (2010
119. Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J . Manidipine treatment in patients with albuminuria not suffi ciently reduced with renin-angiotensin system blockers. Expert Rev. Cardiovasc. Ther. 8 (6), 751 - 757 (2010
120. Ertel EA, Campbell KP, Harpold MM et al. Nomenclature of voltage-gated calcium channels. Neuron 25 (3), 533 - 535 (2000
121. Koichi H, Koichiro H, Shu W et al. T -type Ca channel blockade as a determinant of kidney protection. Keio. J. Med. 59 (3), 84 - 95 (2010
122. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L -type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67 (5), 600 - 606 (2010
123. Kai T, Kuzumoto Y . Effects of a dual L /N-type calcium channel blocker cilnidipine on blood pressure, pulse rate, and autonomic functions in patients with mild to moderate hypertension. Clin. Exp. Hypertens. 31 (7), 595 - 604 (2009